MIND diet to improve thinking and memory after breast cancer
Official title: The MIND-BC Study: MIND Diet for Breast Cancer Cognition
Run by H. Lee Moffitt Cancer Center and Research Institute · NCT07018986 · Data updated 2026-11-12
This trial will try the MIND diet with breast cancer survivors who finished adjuvant treatment 6 months to three years ago and report thinking or memory problems and a low MIND diet score to see if it helps compared with usual diet.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 200 (estimated) |
| Sponsor | H. Lee Moffitt Cancer Center and Research Institute Academic / other |
| Locations | 1 site (Tampa, Florida) |
| Status | Recruiting |
| Started | July 9, 2025 |
| Main results expected | March 2029 |
| Study ends | March 2030 |
| Registry record updated | February 5, 2026 |
| Trial ID | NCT07018986 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are English-speaking adults (age >18) with prior stage I–III breast cancer who completed adjuvant treatment 6 months to three years ago, report recent cognitive problems they attribute to cancer or its treatment, have a low MIND diet score, and are willing to follow the MIND diet.
✕Probably not a fit
Patients who already follow a healthy MIND-like diet, who have cognitive impairment from other neurological or psychiatric conditions, or who do not meet the post-treatment timing requirements are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, controlled intervention at an academic cancer center comparing a structured MIND diet program to usual diet among stage I–III breast cancer survivors reporting cancer-related cognitive impairment and a low baseline MIND diet score. Eligible participants are adults who completed adjuvant treatment 6 months to three years earlier and are willing and able to follow the dietary program. The protocol includes two sequential 12-week phases: an intensive intervention phase followed by a maintenance phase. Primary outcomes focus on cognitive function and diet adherence measured over the intervention and maintenance periods.
Why it matters
Potential benefit: If successful, following the MIND diet could improve thinking, memory, and quality of life for breast cancer survivors with treatment-related cognitive complaints.
How similar studies have gone: Observational studies have linked the MIND diet to better brain health in older adults, but randomized trials testing the MIND diet specifically for cancer-related cognitive impairment are limited, so this approach is relatively novel in this population.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Previously diagnosed with stage I-III breast cancer. * Able to speak and read English. * Able to consume foods orally. * \>18 years of age. * Able to provide informed consent. * Have no documented or observable psychiatric or neurological disorder that would interfere with study participation (e.g., schizophrenia). * Report 'somewhat' to 'very much' cognitive impairment in the past week (i.e., a score ≥ 2 on a 0-4 scale) that they attribute to cancer or its treatment. * Report a MIND diet score \< 10 (range 0 to 14, higher score equates to higher diet quality). * Willing to consume the MIND diet. * Completed adjuvant treatment 6 months to three years previously. Exclusion Criteria: * Not meeting all of the inclusion criteria.
Where it's running
-
Moffitt Cancer Center
Tampa, Florida, United States Recruiting
Study contacts
- Principal investigator: Sylvia Crowder — Moffitt Cancer Center
- Study coordinator: Crystal Bryant
- Email: Crystal.Bryant@moffitt.org
- Phone: 813-745-2168
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.